Author Interviews, Genetic Research, Melanoma / 19.07.2016
DecisionDx-Melanoma Can Determine High Risk Patients Who Require Increased Surveillance
MedicalResearch.com Interview with:
[caption id="attachment_26251" align="alignleft" width="120"]
Dr. Adam Berger[/caption]
Adam Berger, MD, FACS
Vice Chair for Clinical Research
Thomas Jefferson University Hospital
Philadelphia , PA
MedicalResearch.com: What is the background for this study?
Dr. Berger: Perhaps the most important point for consideration in the adoption of a new diagnostic test is: “Will this test impact patient management decisions for the patient that is sitting in front of me?” If the answer is no, then I would not order the test. If this answer is yes, the next question is how does it alter or impact patient management.
The DecisionDx-Melanoma test is a 31-gene expression profile test that has been shown to accurately separate or stratify patients with cutaneous melanoma identified to be at high risk of metastasis (“Class 2” test result) from those who are at an extremely low risk of disease progression (“Class 1” test result).
In two peer-reviewed publications from 2015 and three studies presented between April and June of this year, the DecisionDx-Melanoma test showed a Negative Predictive Value of 98% or 99% for death from melanoma or disease free-survival in patients with Stage I and II melanoma.
Dr. Adam Berger[/caption]
Adam Berger, MD, FACS
Vice Chair for Clinical Research
Thomas Jefferson University Hospital
Philadelphia , PA
MedicalResearch.com: What is the background for this study?
Dr. Berger: Perhaps the most important point for consideration in the adoption of a new diagnostic test is: “Will this test impact patient management decisions for the patient that is sitting in front of me?” If the answer is no, then I would not order the test. If this answer is yes, the next question is how does it alter or impact patient management.
The DecisionDx-Melanoma test is a 31-gene expression profile test that has been shown to accurately separate or stratify patients with cutaneous melanoma identified to be at high risk of metastasis (“Class 2” test result) from those who are at an extremely low risk of disease progression (“Class 1” test result).
In two peer-reviewed publications from 2015 and three studies presented between April and June of this year, the DecisionDx-Melanoma test showed a Negative Predictive Value of 98% or 99% for death from melanoma or disease free-survival in patients with Stage I and II melanoma.























